REFERENCES
- Allen SD, Emery CL, Siders JA. Clostridium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC. 1999.
- Fekety R. Pseudomembranous colitis. In: Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed, WB Saunders Company, Philadelphia, PA. 1996: 1633-1635.
- Wilcox MH, Spencer RC. Clostridium difficile infec-tion: responses, relapses, and re-infections. J Hosp Infection 1992; 22: 85–92.
- Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317–1323.
- Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 1999; 286: 2245–2247.
- Sell TL, Schaberg DR, Fekety FR. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J Clin Microbiol 1983; 17: 1148–1152.
- Dei R. Observations on phage-typing of Clostridium dif-ficile: preliminary evaluation of a phage panel. Eur J Epidemiol 1989; 5: 351–354.
- National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria. 4th ed. Approved Standard M11-A4. NCCLS, Villanova, PA. 1997.
- Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 (Suppl C): 5-12.
- Wilcox MH. Treatment of Clostridium difficile infec-tion. J Antimicrob Chemother 1998; 41 (Suppl C): 41-46.
- Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43 (11): 2607–2611.
- Kerr KG, Copley RM, Wilcox MH. Activity of nisin against Clostridium difficile. Lancet 1997; 349: 1026–1027.